La carboximetilcelulosa, los tampones y los estafilococos.

Crystal structure of a biologically inactive mutant of toxic shock syndrome toxin-1 at 2.5 A resolution.

Protein science : a publication of the Protein Society·1996

A toxic shock syndrome toxin 1 mutant that defines a functional site critical for T-cell activation.

Infection and immunity·1995

Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model.

Infection and immunity·1995

Role of a carboxy-terminal site of toxic shock syndrome toxin 1 in eliciting immune responses of human peripheral blood mononuclear cells.

Infection and immunity·1995

A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity.

Infection and immunity·1995

A fas antigen receptor mutation allows development of toxic shock syndrome toxin-1-induced lethal shock in V beta 8.2 T-cell receptor transgenic mice.

Pathobiology : journal of immunopathology, molecular and cellular biology·1995

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Crystalline Xylan: A Rising Star in Carbohydrate Materials.

Biomacromolecules·2026

Carbon framework controlled charge storage and ion-transport dynamics in hydrothermally synthesized MnS nanocomposite electrodes for advanced supercapacitors.

RSC advances·2026

Acyclic Hydrocarbon α,ω-Dienes: From Biomass and Plastic Upcycling to Carbocycles, Precision Polymers, and Cross-Linked Elastomers.

ChemSusChem·2026

Covalent organic framework monoliths: structures, applications and biomimetic opportunities.

Materials horizons·2026

Adult Presentation of Congenital Macrodactyly of the Hand Managed with Debulking and Amputation of a Digit: Report of a Rare Case.

Journal of orthopaedic case reports·2026

Hybrid clay-biopolymer nanocomposites as multifunctional materials for biomedical and environmental applications.

Advances in colloid and interface science·2026

Videos de Experimentos Relacionados

La carboximetilcelulosa, los tampones y los estafilococos.

Videos de Conceptos Relacionados

Crystal structure of a biologically inactive mutant of toxic shock syndrome toxin-1 at 2.5 A resolution.

A toxic shock syndrome toxin 1 mutant that defines a functional site critical for T-cell activation.

Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model.

Role of a carboxy-terminal site of toxic shock syndrome toxin 1 in eliciting immune responses of human peripheral blood mononuclear cells.

A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity.

A fas antigen receptor mutation allows development of toxic shock syndrome toxin-1-induced lethal shock in V beta 8.2 T-cell receptor transgenic mice.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Crystalline Xylan: A Rising Star in Carbohydrate Materials.

Carbon framework controlled charge storage and ion-transport dynamics in hydrothermally synthesized MnS nanocomposite electrodes for advanced supercapacitors.

Acyclic Hydrocarbon α,ω-Dienes: From Biomass and Plastic Upcycling to Carbocycles, Precision Polymers, and Cross-Linked Elastomers.

Covalent organic framework monoliths: structures, applications and biomimetic opportunities.

Adult Presentation of Congenital Macrodactyly of the Hand Managed with Debulking and Amputation of a Digit: Report of a Rare Case.

Hybrid clay-biopolymer nanocomposites as multifunctional materials for biomedical and environmental applications.

Videos de Experimentos Relacionados

La carboximetilcelulosa, los tampones y los estafilococos.

Videos de Conceptos Relacionados

Artículos Relacionados